Concentrations of VP16 and VM26 in human brain tumors - PubMed (original) (raw)
Concentrations of VP16 and VM26 in human brain tumors
M Zucchetti et al. Ann Oncol. 1991 Jan.
Free article
Abstract
VP16 and VM26 were determined by high pressure liquid chromatography in intracerebral tumors, adjacent normal brain tissue, plasma and CSF samples from 24 patients given the two drugs before surgical resection of the tumor. The drugs were administered at doses of 100-150 mg/m2 as a 1-hour i.v. infusion, between 1.5 and 12 hours before surgery. Concentrations of VP16 ranged between 1.05 and 3.28 micrograms/g in tumors in the series of patients who received the drug 1.5-3 hours before surgery and between less than 0.05 and 1.12 micrograms/g in four patients who received the drug 9-13 hours before surgery. Tumor concentrations of VM26 also varied, ranging from less than 0.05 to 1.68 micrograms/g between 1.5 and 12 hours before surgery. VP16 and VM26 in the apparently normal brain tissue surrounding the tumor were low or undetectable except in one patient who had received radiotherapy, in whom we found 3.1 micrograms/g.
Similar articles
- Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?
Allen LM, Tejada F, Okonmah AD, Nordqvist S. Allen LM, et al. Cancer Chemother Pharmacol. 1982;7(2-3):151-6. doi: 10.1007/BF00254538. Cancer Chemother Pharmacol. 1982. PMID: 7083456 - Human cytochrome P450 metabolism of teniposide and etoposide.
Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Relling MV, et al. J Pharmacol Exp Ther. 1992 May;261(2):491-6. J Pharmacol Exp Ther. 1992. PMID: 1578365 - Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G. Evans WE, et al. Cancer Chemother Pharmacol. 1982;7(2-3):147-50. doi: 10.1007/BF00254537. Cancer Chemother Pharmacol. 1982. PMID: 7083455 - The clinical pharmacology of VM26 and VP16-213. A brief overview.
Creaven PJ. Creaven PJ. Cancer Chemother Pharmacol. 1982;7(2-3):133-40. doi: 10.1007/BF00254535. Cancer Chemother Pharmacol. 1982. PMID: 7044592 Review. No abstract available. - Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives.
Clark PI. Clark PI. Semin Oncol. 1992 Apr;19(2 Suppl 6):20-7. Semin Oncol. 1992. PMID: 1411635 Review.
Cited by
- Tissue concentration of systemically administered antineoplastic agents in human brain tumors.
Pitz MW, Desai A, Grossman SA, Blakeley JO. Pitz MW, et al. J Neurooncol. 2011 Sep;104(3):629-38. doi: 10.1007/s11060-011-0564-y. Epub 2011 Mar 12. J Neurooncol. 2011. PMID: 21400119 Free PMC article. Review. - Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.
Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, Realubit R, Li H, Karan C, Yun J, Showers C, Rothcock R, O J, Califano A, Canoll P, Bruce JN. Sonabend AM, et al. Neuro Oncol. 2014 Sep;16(9):1210-9. doi: 10.1093/neuonc/nou026. Epub 2014 Mar 16. Neuro Oncol. 2014. PMID: 24637229 Free PMC article. - Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy.
Mehta A, Awah CU, Sonabend AM. Mehta A, et al. Front Neurol. 2018 Jun 20;9:459. doi: 10.3389/fneur.2018.00459. eCollection 2018. Front Neurol. 2018. PMID: 29988316 Free PMC article. Review. - Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Sarkaria JN, et al. Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Neuro Oncol. 2018. PMID: 29016900 Free PMC article. Review. - Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments.
Lago C, Federico A, Leva G, Mack NL, Schwalm B, Ballabio C, Gianesello M, Abballe L, Giovannoni I, Reddel S, Rossi S, Leone N, Carai A, Mastronuzzi A, Bisio A, Soldano A, Quintarelli C, Locatelli F, Kool M, Miele E, Tiberi L. Lago C, et al. EMBO Mol Med. 2023 Dec 7;15(12):e18199. doi: 10.15252/emmm.202318199. Epub 2023 Nov 30. EMBO Mol Med. 2023. PMID: 38037472 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical